Literature DB >> 23073862

Fabry disease: raising awareness of the disease among physicians.

Francesca Carubbi1, Lisa Bonilauri.   

Abstract

Fabry disease is an X-linked inherited lysosomal disorder due to dysfunctions of the lysosomal enzyme alpha-galactosidase A, causing insufficient breakdown of glycolipids, which are stored in the eyes, kidneys, autonomic nervous system, skin, vessels and cardiovascular system. Manifestations of Fabry disease include progressive renal and cardiac insufficiency, neuropathic pain, stroke and cerebral disease, skin and gastrointestinal symptoms. Clinical onset usually occurs in childhood, but many severe patients are diagnosed in adulthood. Females may be severely affected as males and both may die prematurely due to stroke, heart disease and renal failure. Enzyme replacement therapy can stabilize or reduce the progression of the disease. There is a need to improve the knowledge of Fabry disease, as an early therapy may prevent complications of the disease. This brief overview aims to raise awareness of the signs and symptoms of Fabry disease and to summarize the effects of treatments.

Entities:  

Mesh:

Year:  2012        PMID: 23073862     DOI: 10.1007/s11739-012-0821-x

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  40 in total

1.  Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization.

Authors:  Maurizio Pieroni; Cristina Chimenti; Francesco De Cobelli; Emanuela Morgante; Alessandro Del Maschio; Carlo Gaudio; Matteo Antonio Russo; Andrea Frustaci
Journal:  J Am Coll Cardiol       Date:  2006-03-29       Impact factor: 24.094

2.  Hearing loss in Fabry disease: data from the Fabry Outcome Survey.

Authors:  S Hegemann; D Hajioff; G Conti; M Beck; G Sunder-Plassmann; U Widmer; A Mehta; A Keilmann
Journal:  Eur J Clin Invest       Date:  2006-09       Impact factor: 4.686

3.  Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.

Authors:  U Ramaswami; S Wendt; G Pintos-Morell; R Parini; C Whybra; J A Leon Leal; F Santus; M Beck
Journal:  Acta Paediatr       Date:  2007-01       Impact factor: 2.299

4.  An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

Authors:  S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

5.  Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Authors:  A Mehta; M Beck; P Elliott; R Giugliani; A Linhart; G Sunder-Plassmann; R Schiffmann; F Barbey; M Ries; J T R Clarke
Journal:  Lancet       Date:  2009-12-12       Impact factor: 79.321

Review 6.  Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.

Authors:  Roland M Schaefer; Anna Tylki-Szymańska; Max J Hilz
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

7.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

8.  Neurology of Fabry disease.

Authors:  M Low; K Nicholls; N Tubridy; P Hand; D Velakoulis; L Kiers; P Mitchell; G Becker
Journal:  Intern Med J       Date:  2007-07       Impact factor: 2.048

9.  Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.

Authors:  Stephen Waldek; Manesh R Patel; Maryam Banikazemi; Roberta Lemay; Philip Lee
Journal:  Genet Med       Date:  2009-11       Impact factor: 8.822

10.  Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.

Authors:  Anouk C Vedder; Gabor E Linthorst; Gunnar Houge; Johannna E M Groener; Els E Ormel; Berto J Bouma; Johannes M F G Aerts; Asle Hirth; Carla E M Hollak
Journal:  PLoS One       Date:  2007-07-11       Impact factor: 3.240

View more
  2 in total

1.  A painful diagnosis.

Authors:  Paolo Fraticelli; Marco Cardinali; Lorenzo Biondi; Devis Benfaremo; Massimo Mattioli; Roberta Mazzucchelli; Rodolfo Montironi; Armando Gabrielli
Journal:  Intern Emerg Med       Date:  2017-02-25       Impact factor: 3.397

2.  A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide.

Authors:  Atul Mehta; Uma Ramaswami; Joseph Muenzer; Roberto Giugliani; Kurt Ullrich; Tanya Collin-Histed; Zoya Panahloo; Hartmann Wellhoefer; Joel Frader
Journal:  Orphanet J Rare Dis       Date:  2021-01-06       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.